Your browser is no longer supported. Please, upgrade your browser.
Organovo Holdings, Inc.
Index- P/E- EPS (ttm)-2.57 Insider Own0.40% Shs Outstand6.86M Perf Week-16.24%
Market Cap81.06M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float6.62M Perf Month-25.16%
Income-17.00M PEG- EPS next Q- Inst Own42.20% Short Float4.05% Perf Quarter28.67%
Sales0.00M P/S- EPS this Y37.40% Inst Trans-0.68% Short Ratio0.60 Perf Half Y30.56%
Book/sh3.03 P/B3.52 EPS next Y- ROA-70.40% Target Price- Perf Year63.25%
Cash/sh2.48 P/C4.31 EPS next 5Y- ROE-73.60% 52W Range3.87 - 23.92 Perf YTD-13.17%
Dividend- P/FCF- EPS past 5Y17.50% ROI-80.70% 52W High-55.35% Beta0.82
Dividend %- Quick Ratio- Sales past 5Y30.90% Gross Margin- 52W Low176.25% ATR2.09
Employees6 Current Ratio24.20 Sales Q/Q- Oper. Margin- RSI (14)38.97 Volatility15.35% 15.82%
OptionableYes Debt/Eq0.00 EPS Q/Q29.10% Profit Margin- Rel Volume0.79 Prev Close11.39
ShortableNo LT Debt/Eq0.00 Earnings- Payout- Avg Volume444.04K Price10.68
Recom3.00 SMA20-28.71% SMA50-24.83% SMA200-5.21% Volume351,697 Change-6.23%
Dec-13-18Initiated H.C. Wainwright Buy $2.50
Nov-10-17Downgrade Raymond James Outperform → Mkt Perform
Jan-25-17Initiated Raymond James Outperform
Aug-11-15Downgrade Cantor Fitzgerald Buy → Hold
Jun-29-15Initiated Piper Jaffray Overweight $5
Jun-29-15Initiated Jefferies Buy $5
Mar-02-21 08:05AM  
Feb-07-21 09:19AM  
Sep-03-20 04:05PM  
Aug-17-20 08:05AM  
Jun-10-20 03:43PM  
Apr-08-20 10:32AM  
Apr-07-20 04:12PM  
Apr-02-20 08:00AM  
Mar-31-20 06:30PM  
Mar-28-20 02:27PM  
Mar-27-20 04:05PM  
Mar-23-20 03:30PM  
Mar-19-20 02:36PM  
Feb-26-20 08:30AM  
Jan-21-20 07:00AM  
Jan-07-20 08:00AM  
Dec-17-19 07:03PM  
Dec-16-19 07:00AM  
Nov-21-19 07:19AM  
Nov-18-19 09:18AM  
Nov-15-19 07:06AM  
Nov-07-19 10:30AM  
Oct-03-19 07:34AM  
Oct-02-19 07:31PM  
Sep-11-19 01:29PM  
Sep-06-19 09:36AM  
Aug-08-19 08:50PM  
Aug-07-19 09:00AM  
Aug-01-19 10:32AM  
Jul-18-19 08:05AM  
Jul-09-19 02:59PM  
Jul-08-19 08:05AM  
Jun-26-19 06:57AM  
Jun-25-19 08:37AM  
Jun-13-19 08:05AM  
Jun-10-19 12:36PM  
Jun-05-19 01:16AM  
May-30-19 08:05AM  
May-24-19 07:44AM  
May-22-19 04:05PM  
May-17-19 08:05AM  
Apr-26-19 01:01PM  
Apr-17-19 08:05AM  
Mar-14-19 08:05AM  
Feb-20-19 08:05AM  
Feb-13-19 03:29AM  
Feb-12-19 07:45AM  
Feb-08-19 02:35PM  
Feb-07-19 06:40PM  
Jan-31-19 10:31AM  
Jan-22-19 10:57AM  
Jan-17-19 08:05AM  
Dec-06-18 08:05AM  
Dec-04-18 06:19PM  
Nov-12-18 08:05AM  
Nov-08-18 07:30PM  
Oct-18-18 08:05AM  
Oct-17-18 07:30AM  
Oct-15-18 08:05AM  
Sep-26-18 08:05AM  
Sep-19-18 02:27PM  
Aug-27-18 03:50PM  
Aug-14-18 08:15PM  
Aug-10-18 07:38AM  
Aug-09-18 07:20PM  
Aug-01-18 08:05AM  
Jul-20-18 07:25AM  
Jul-19-18 08:05AM  
Jun-05-18 12:03PM  
Jun-01-18 03:04PM  
May-31-18 04:30PM  
May-18-18 07:15PM  
May-16-18 07:55AM  
May-14-18 08:05AM  
May-10-18 08:05AM  
May-03-18 08:05AM  
Apr-18-18 09:50AM  
Apr-16-18 08:05AM  
Apr-12-18 08:05AM  
Mar-26-18 08:05AM  
Mar-15-18 08:05AM  
Mar-08-18 08:05AM  
Feb-09-18 09:56AM  
Feb-08-18 06:41PM  
Organovo Holdings, Inc., a biotechnology company, develops bioprinted human tissues based on its 3D human tissue platform technology that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases; and NovoTissues liver product using cells from a liver donor and cells from an umbilical cord donor. The company was founded in 2007 and is headquartered in Solana Beach, California.